Mapping functional to morphological variation reveals the basis of regional extracellular matrix subversion and nerve invasion in pancreatic cancer.

PDAC extracellular matrix histology laser microdissection pancreatic cancer perineural invasion spatial transcriptomics tumor heterogeneity tumor microenvironment

Journal

Cancer cell
ISSN: 1878-3686
Titre abrégé: Cancer Cell
Pays: United States
ID NLM: 101130617

Informations de publication

Date de publication:
18 Mar 2024
Historique:
received: 21 12 2022
revised: 07 12 2023
accepted: 27 02 2024
medline: 23 3 2024
pubmed: 23 3 2024
entrez: 22 3 2024
Statut: aheadofprint

Résumé

Intratumor morphological heterogeneity of pancreatic ductal adenocarcinoma (PDAC) predicts clinical outcomes but is only partially understood at the molecular level. To elucidate the gene expression programs underpinning intratumor morphological variation in PDAC, we investigated and deconvoluted at single cell level the molecular profiles of histologically distinct clusters of PDAC cells. We identified three major morphological and functional variants that co-exist in varying proportions in all PDACs, display limited genetic diversity, and are associated with a distinct organization of the extracellular matrix: a glandular variant with classical ductal features; a transitional variant displaying abortive ductal structures and mixed endodermal and myofibroblast-like gene expression; and a poorly differentiated variant lacking ductal features and basement membrane, and showing neuronal lineage priming. Ex vivo and in vitro evidence supports the occurrence of dynamic transitions among these variants in part influenced by extracellular matrix composition and stiffness and associated with local, specifically neural, invasion.

Identifiants

pubmed: 38518775
pii: S1535-6108(24)00079-5
doi: 10.1016/j.ccell.2024.02.017
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests L.M. reports research funding from Bristol-Myers Squibb and Roche, and consulting fees from Tethis, which are all unrelated to the content of this study.

Auteurs

Pierluigi Di Chiaro (P)

Department of Experimental Oncology, IEO, European Institute of Oncology IRCCS, Milano, Italy. Electronic address: pierluigi.dichiaro@ieo.it.

Lucia Nacci (L)

Department of Experimental Oncology, IEO, European Institute of Oncology IRCCS, Milano, Italy.

Fabiana Arco (F)

Department of Experimental Oncology, IEO, European Institute of Oncology IRCCS, Milano, Italy.

Stefania Brandini (S)

Department of Experimental Oncology, IEO, European Institute of Oncology IRCCS, Milano, Italy.

Sara Polletti (S)

Department of Experimental Oncology, IEO, European Institute of Oncology IRCCS, Milano, Italy.

Andrea Palamidessi (A)

IFOM, The FIRC Institute for Molecular Oncology, Via Adamello 16, 20139 Milan, Italy.

Benedetta Donati (B)

Laboratory of Translational Research, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy.

Chiara Soriani (C)

Department of Experimental Oncology, IEO, European Institute of Oncology IRCCS, Milano, Italy.

Francesco Gualdrini (F)

Department of Experimental Oncology, IEO, European Institute of Oncology IRCCS, Milano, Italy.

Gianmaria Frigè (G)

Department of Experimental Oncology, IEO, European Institute of Oncology IRCCS, Milano, Italy.

Luca Mazzarella (L)

Department of Experimental Oncology, IEO, European Institute of Oncology IRCCS, Milano, Italy; Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, IEO, European Institute of Oncology, IRCCS, Milano, Italy.

Alessia Ciarrocchi (A)

Laboratory of Translational Research, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy.

Alessandro Zerbi (A)

IRCCS Humanitas Research Hospital, Rozzano, Milano, Italy; Humanitas University, Pieve Emanuele - Milano, Italy.

Paola Spaggiari (P)

IRCCS Humanitas Research Hospital, Rozzano, Milano, Italy.

Giorgio Scita (G)

IFOM, The FIRC Institute for Molecular Oncology, Via Adamello 16, 20139 Milan, Italy; Department of Oncology and Haemato-Oncology, University of Milan, Milano, Italy.

Simona Rodighiero (S)

Department of Experimental Oncology, IEO, European Institute of Oncology IRCCS, Milano, Italy.

Iros Barozzi (I)

Center for Cancer Research, Medical University of Vienna, Vienna, Austria.

Giuseppe R Diaferia (GR)

Department of Experimental Oncology, IEO, European Institute of Oncology IRCCS, Milano, Italy. Electronic address: giuseppe.diaferia@ieo.it.

Gioacchino Natoli (G)

Department of Experimental Oncology, IEO, European Institute of Oncology IRCCS, Milano, Italy. Electronic address: gioacchino.natoli@ieo.it.

Classifications MeSH